Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing ...

This week's dividend activity included increased payouts from Pepsico (NASDAQ:PEP) and KLA (KLAC) as well as declarations ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, raised a $130 million Series B round.

The new research and development site will combine research, process development and clinical trial manufacturing ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Eli Lilly has broken ground on a massive new research facility in Lebanon that will support hundreds of jobs and focus on ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...